2 weeks Ago By ABMN Staff
Rhumbline Advisers trimmed its holdings in shares of Akoya Biosciences, Inc. ( NASDAQ:AKYA – Free Report ) by 15.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The firm owned 28,732 shares of the company’s stock after selling 5,125 shares during the period. Rhumbline Advisers’ holdings in Akoya Biosciences were worth $67,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently modified their holdings of AKYA.
CIBC Asset Management Inc boosted its holdings in Akoya Biosciences by 176.0% during the 4th quarter. CIBC Asset Management Inc now owns 115,644 shares of the company’s stock valued at $564,000 after acquiring an additional 73,737 shares during the period.
Parkman Healthcare Partners LLC increased its holdings in Akoya Biosciences by 28.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 674,787 shares of the company’s stock valued at $3,293,000 after purchasing an additional 149,164 shares during the period.
Vanguard Group Inc. lifted its stake in Akoya Biosciences by 3.3% in the first quarter.
Vanguard Group Inc. now owns 1,454,288 shares of the company’s stock worth $6,821,000 after acquiring an additional 46,131 shares during the period. Silvercrest Asset Management Group LLC purchased a new position in Akoya Biosciences during the 1st quarter valued at $2,724,000.
Finally, Bank of New York Mellon Corp lifted its holdings in Akoya Biosciences by 16.2% in the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after buying an additional 9,429 shares during the period.
79.42% of the stock is owned by institutional investors. Akoya Biosciences Price Performance NASDAQ AKYA opened at $2.
72 on Tuesday. The company’s 50 day moving average is $2.49 and its two-hundred day moving average is $2.
95. The company has a current ratio of 2.73, a quick ratio of 1.
98 and a debt-to-equity ratio of 3.43. The stock has a market cap of $134.
33 million, a price-to-earnings ratio of -1.85 and a beta of 1.35.
Akoya Biosciences, Inc. has a 12 month low of $1.88 and a 12 month high of $6.
31. Analyst Upgrades and Downgrades Several research firms recently weighed in on AKYA. BTIG Research lowered Akoya Biosciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th.
Morgan Stanley cut shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $4.00 to $3.00 in a report on Tuesday, August 6th.
JPMorgan Chase & Co. cut Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th. Craig Hallum reduced their price target on Akoya Biosciences from $7.
50 to $7.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, Piper Sandler lowered their price target on Akoya Biosciences from $6.
00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company.
According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.56.
View Our Latest Research Report on Akoya Biosciences Akoya Biosciences Profile ( Free Report ) Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. Read More Want to see what other hedge funds are holding AKYA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Akoya Biosciences, Inc. ( NASDAQ:AKYA – Free Report ). Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
